Table 2

Idiopathic PAH clinical summary

Patient	Sex	Age (years)	Mean PAP (mm Hg)	PVR (units⋅m²)	Pre-epo	Treatment duration (months)	Epo added	WHO class		Six minutes walk		Weight (kg)
Patient	Sex	Age (years)	Mean PAP (mm Hg)	PVR (units⋅m²)	Pre-epo	Treatment duration (months)	Epo added	Baseline	Change with bosentan	Baseline	% Change with bosentan	Baseline	% Change with bosentan
F, female; M, male; pre-epo, receiving epoprostenol before treatment with bosentan.
1(died)	F	1.2	31	12.3	No	4	No	IV				8	2.5
2	M	1.2	91	23.9	No	10	No	III	0			8.5	18
3	F	2.3	71	33	No	20	Yes	IV	0			12.8	14
4	M	2.7	89	38.9	Yes	15	No	IV	−1			9	33
5	F	3.4	74	18.6	No	19	No	III	0			10.3	30
6	F	3.9	65	42.8	No	14	Yes	III	1			16.3	3
7	F	4.1	25	12	No	11	Yes	III	1			14.3	10.4
8	M	4.3	54	13.5	No	18	Yes	IV	0			17.4	4
9	F	5.4	50	14.6	No	22	No	III	0			17.4	19
10	F	5.5	71	23	No	18	Yes	IV	0			15.7	28
11	M	7.2	66	18.6	Yes	3	No	III	−1	262	−14	20.9	−3.3
12	F	7.8	68	30	Yes	11	No	III	−1	180	83	17.1	−2.9
13	M	9.75	59	18.5	Yes	21	No	III	0	315	−1.9	28.8	13.8
14	F	12.4	68	16.1	No	7	No	III	0	334	−43	31	−2.5
15	F	12.5	61	16.9	No	11	No	III	−1	250	92	57.5	12.8
16	F	13.7	49	18	No	4	No	IV	−1	430	−2.3	55	1.8
17	F	14.6	25	5.6	Yes	9	No	II	0	300	21.3	52.6	−7.4
18	F	15.5	51	12.5	No	12	No	III	−1	140	157	51.3	−2.1
19	F	16.2	88	27	Yes	24	No	IV	−1	80	275	36.9	19
20	F	17	73	39	Yes	10	No	IV	−1	160	−0.6	70	−1.1